Results 1 to 10 of about 301,002 (287)

Hepatitis B vaccine development and implementation

Human Vaccines & Immunotherapeutics, 2020
Vaccination against hepatitis B is the most effective strategy to control HBV infection. The first licensed hepatitis B vaccine was developed by the purification of hepatitis B surface antigen (HBsAg) from plasma of asymptomatic HBsAg carriers. Then, the
Hong Zhao, Xiaoying Zhou, Yi-Hua Zhou
doaj   +2 more sources

Influences of obesity on the immunogenicity of Hepatitis B vaccine

Human Vaccines & Immunotherapeutics, 2017
Objective: Hepatitis B vaccine is regarded as the most effective method for the prevention of hepatitis B virus (HBV) infection. However, several factors such as age, body mass index and immunocompetent state have been reported to be associated with ...
Fang Liu, Zhirong Guo, Chen Dong
doaj   +2 more sources

Hepatitis B vaccine knowledge and self-reported vaccination status among healthcare workers in a conflict region in northeastern Nigeria

Therapeutic Advances in Vaccines and Immunotherapy, 2020
Background Hepatitis B virus (HBV) infection is highly endemic in Nigeria. The primary objective of this study is to describe the knowledge, self-reported vaccination status, and intention of healthcare workers to receive hepatitis B vaccine at a ...
Farouq Muhammad Dayyab, Garba Iliyasu, Bashir Garba Ahmad, Abdulaziz Tijjani Bako, Sepu Saraya Ngamariju, Abdulrazaq Garba Habib   +5 more
doaj   +2 more sources

A controlled clinical trial of the efficacy of the hepatitis B vaccine (heptavax B): A final report [PDF]

Hepatology, 1981
W. Szmuness, Cladd E. Stevens, Edith Zang, Edward J. Harley, Aaron Kellner   +4 more
openalex   +2 more sources

Action Mechanisms and Scientific Rationale of Using Nasal Vaccine (HeberNasvac) for the Treatment of Chronic Hepatitis B

Vaccines, 2022
Nasvac (HeberNasvac®) is a novel therapeutic vaccine for chronic hepatitis B (CHB). This product is a formulation of the core (HBcAg) and surface (HBsAg) antigens of the hepatitis B virus (HBV), administered by nasal and subcutaneous routes, in a ...
Julio Cesar Aguilar, Jorge Agustin Aguiar, Sheikh Mohammad Fazle Akbar   +2 more
doaj   +1 more source

Protection and antibody levels 35 years after primary series with hepatitis B vaccine and response to a booster dose

Hepatology, 2022
The duration of protection from hepatitis B vaccination in children and adults is not known. In 1981, we used three doses of plasma‐derived hepatitis B vaccine to immunize a cohort of 1578 Alaska Native adults and children from 15 Alaska communities who ...
M. Bruce, Dana Bruden, D. Hurlburt, J. Morris, Sara S. Bressler, G. Thompson, Danielle Lecy, K. Rudolph, L. Bulkow, T. Hennessy, Brenna C. Simons, Mark K. Weng, Noele P. Nelson, B. McMahon   +13 more
semanticscholar   +1 more source

Knowledge and associated factors for the uptake of hepatitis B vaccine among nonmedical undergraduate students in a private university in Ekiti State, Nigeria

Nigerian Journal of Medicine, 2022
Background: Hepatitis B is a life-threatening viral infection that causes acute and chronic diseases of the liver. Hepatitis B infection is endemic in Nigeria with a national pooled prevalence rate of 9.5%.
Olusegun Elijah Elegbede, Ayodele Kamal Alabi, Taiye Adeyanju Alao, Taofeek Adedayo Sanni   +3 more
doaj   +1 more source

Inspiration to mRNA-based COVID-19 vaccination: Serious adverse case reports with hepatitis B vaccine in real-world

Frontiers in Pediatrics, 2022
ObjectivesThe hepatitis B vaccine comprises hepatitis B surface antigen (HBsAg) produced by transgenic yeast cells. There are few serious adverse events (SAE) reports after Hepatitis B vaccination.MethodsThe authors searched the Chinese legal documents ...
Jinmiao Lu, Xunjie Zhang, Hong Xu, Zhiping Li   +3 more
doaj   +1 more source

Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine

JAMA Network Open, 2021
Key Points Question What is the immunogenicity and safety of a 3-antigen hepatitis B virus (HBV) vs a single-antigen HBV vaccine among young adults? Findings This randomized clinical trial of 2838 participants found that the 3-antigen HBV vaccine was ...
T. Vesikari, A. Finn, P. van Damme, I. Leroux-Roels, G. Leroux-Roels, N. Segall, Azhar Toma, G. Vallieres, R. Aronson, D. Reich, S. Arora, P. Ruane, Clancy L Cone, M. Manns, C. Cosgrove, S. Faust, M. Ramasamy, Nathalie Machluf, J. Spaans, B. Yassin-Rajkumar, D. Anderson, V. Popovic, F. Diaz-Mitoma   +22 more
semanticscholar   +1 more source

Hepatitis B Vaccines [PDF]

The Journal of Infectious Diseases, 2017
Abstract Hepatitis B is caused by the hepatitis B virus (HBV), which infects the liver and may lead to chronic liver disease, including cirrhosis and hepatocellular carcinoma. HBV represents a worldwide public health problem, causing major morbidity and mortality.
Pattyn, Jade, Hendrickx, Greet, Vorsters, Alex, van Damme, Pierre   +3 more
openaire   +4 more sources